


hemotune AG appoints Dr. Eduard Ayuso as a member of the Board of Directors

Schlieren, Switzerland, October 01, 2026: hemotune AG, a pioneering Swiss medtech company, today announced the appointment of Dr. Eduard Ayuso to the Board of Directors. He takes over from Didier Cowling, who steps down after more than seven years on the Board, including as President until 2023.

Eduard Ayuso, DVM, PhD, has more than two decades experience at the centre of gene therapy and viral vector manufacturing. He is CTO of Siegfried DINAMIQS, which he co-founded in 2022. As a founder CEO, he led its acquisition by the Siegfried Group within twelve months. Previously, as CTO of DINAQOR, he established labs at Bio-Technopark Schlieren-Zürich, developed a concept for a GMP facility for viral vector manufacturing and contributed to fundraising and partnering with venture capital and strategic investors. A pioneer in viral vectors for therapeutic applications, he combines a strong scientific and technical background with a clear client and patient focus and has built his career on trusted partnerships and a broad network in cell and gene therapy. Eduard has authored more than 50 scientific publications and chaired the manufacturing committee of the European Society of Gene and Cell Therapy.



hemotune's magnetic bead platform has been through preclinical development and is now being applied to both sides of the gene therapy bottleneck: removing pre-existing neutralizing antibodies so that systemic AAV therapies can reach the patients excluded from them today, and the downstream processing of biologics. Very few people understand both sides from the inside as Eduard does.

Eduard on joining: "I am excited to join hemotune's Board and support its ambition to redefine what is possible in gene therapy. By overcoming neutralizing antibodies to unlock systemic AAV treatments and advancing a powerful magnetic bead platform for next-generation bioprocessing, hemotune has the potential to transform both patient access and the manufacturing of biologics."

Dr. Harald Casebourne Stock, President of hemotune's Board of Directors, says: "On behalf of the Board, I want to thank Didier for his many years of service. His contributions have been instrumental in establishing hemotune's leadership in magnetic nanoparticle technology, and we wish him all the best. At the same time, we're delighted to welcome Eduard, whose experience in the advanced therapeutic modalities space will be a great asset as we enter our next phase. I look forward to



working with him, our fellow Directors, and CEO Lukas Langenegger and the leadership team to shape hemotune's future."

We look forward to what Eduard's experience will bring as we take our programmes towards patients.

About hemotune AG

hemotune AG is a pioneering biotech company based in Schlieren, Switzerland. Leveraging nanotechnology, hemotune AG implements precision medicine treatments through its groundbreaking blood purification platform. Founded in 2017 as a spin-off from ETH Zurich, the company has rapidly emerged as a new leader in the field.

Recognized for its innovation and impact, hemotune AG has won numerous awards, including the prestigious Swiss Technology Award 2020 and recognition as a top spin-off to watch by Forbes magazine in 2021. Additionally, in 2022 hemotune AG has been nominated for the Swiss Economic Award and was recognized with the Technology Innovation Leadership Award by Frost and Sullivan underscoring its position as a frontrunner in the healthcare sector. In 2023, hemotune AG was selected as one of Switzerland's most innovative companies by Bilanz and won two Medical Device Excellence awards by GlobalData.

hemotune AG is committed to pushing the boundaries of healthcare and delivering transformative solutions that have the potential to redefine patient care worldwide. For more information, please visit www.hemotune.com.

Contact

Lukas Langenegger, CEO
Phone: +41 77 512 36 98
Email: info@hemotune.ch